Post-earnings recap
Reported
Thu, May 5, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Celldex Therapeutics reported a loss per share that was slightly worse than expected, contributing to a 5.57% decline in stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's financial health and future prospects. The management's focus on clinical programs suggests they are prioritizing long-term growth over short-term financial performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.49 | N/A | -7.22% |
| Revenue | N/A | N/A | N/A |
Management expressed a commitment to their ongoing projects but did not provide a clear outlook for future performance. The tone was cautious, reflecting the challenges faced in the quarter.
Management did not provide specific revenue guidance for the upcoming quarters.
The company is focused on advancing its clinical programs despite the current financial results.